Novacyt (NCYT) Share Price, News & Analysis

Company Overview

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Key Stats

• Today's Range: 69 to 73.13
• 50-Day Range: 44.50 to 118
• 52-Week Range: 39.07 to 137
• Volume: 97,599 shs
• Average Volume: 614,887 shs
• Market Capitalization: £50.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NCYT Stock Analysis - Frequently Asked Questions

How have NCYT shares performed this year?

Novacyt's stock was trading at GBX 61.50 at the start of the year. Since then, NCYT stock has increased by 16.3% and is now trading at GBX 71.50.
View the best growth stocks for 2024 here.

How do I buy shares of Novacyt?

Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS) and Verastem (VSTM).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:NCYT
• CUSIP: N/A
• CIK: N/A
• Web: www.novacyt.com
• Phone: 33 1 39 46 51 04
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-27,800,000.00
• Net Margins: -244.34%
• Pretax Margin: N/A
• Return on Equity: -27.46%
• Return on Assets: -13.43%

Debt

• Debt-to-Equity Ratio: 15.71
• Current Ratio: 2.92
• Quick Ratio: 4.46

Sales & Book Value

• Annual Sales: £11.58 million
• Price / Sales: 4.40
• Cash Flow: GBX 124.40 per share
• Price / Cash Flow: 0.58
• Book Value: GBX 124 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 70,630,000
• Free Float: N/A
• Market Cap: £50.99 million
• Optionable: Not Optionable
• Beta: -1.86